Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jaguar Health, Inc. - Common Stock (NQ:JAGX)

0.3985 -0.0080 (-1.97%)
Streaming Delayed Price Updated: 1:19 PM EDT, Apr 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Jaguar Health, Inc. - Common Stock

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
News headline image
Jaguar Health Achieves Approximately 75% Enrollment in Pivotal Phase 3 OnTarget Trial of Crofelemer for Cancer Therapy-Related Diarrhea
Via ACCESSWIRE
News headline image
Jaguar Health Announces Initial Close in Private Placement Financing Round for Napo Therapeutics S.p.A.
Via ACCESSWIRE
News headline image
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
Via ACCESSWIRE
News headline image
Jaguar Health & SynWorld Technologies Mutually Agree to Terminate License and Commercialization Agreement for Canalevia for Treatment of Diarrhea in Dogs in China Given Jaguar’s 2023 Focus on Human Drug Development
Via ACCESSWIRE
News headline image
Jaguar Health Engages Shareholder Intelligence Services, LLC (ShareIntel) to Monitor Trading Activity in Effort to Identify Possible Illegal Short Selling
Via ACCESSWIRE
News headline image
Jaguar Health Engages Former FDA Gastroenterology Division Deputy Director Andrew Mulberg, M.D. to Bolster Company's Regulatory Expertise
Via ACCESSWIRE
News headline image
Jaguar Health Reports Voting Results from January 2023 Special Meeting of Stockholders
Via ACCESSWIRE
News headline image
Jaguar Health Subsidiary Napo Pharmaceuticals Sponsors Episode of The Gayly Dose Focused on HIV-related Diarrhea
Via ACCESSWIRE
News headline image
Jaguar Health Hosts Symposium on the Management of Cancer Therapy-related Diarrhea
Via ACCESSWIRE
News headline image
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Via ACCESSWIRE
News headline image
Jaguar Health Provides Updates Regarding Company's Focus on Rare and Orphan Disease Indications in the U.S. & Europe
Via ACCESSWIRE
News headline image
Jaguar Health Announces Completion of Key Milestone in Process of Establishing Indena S.p.A. as a Reliable Approved Crofelemer Manufacturer
Via ACCESSWIRE
News headline image
Jaguar Health Announces Establishment of Board of Directors for Newly Formed Joint Venture Magdalena Biosciences
Via ACCESSWIRE
News headline image
Jaguar Health to Present at Lytham Partners Investor Select Conference on January 31st
Via ACCESSWIRE
News headline image
REMINDER: Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar’s Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies
Via ACCESSWIRE
News headline image
Jaguar Health Provides Company Updates and Reports 2022 Third Quarter Financials
Via ACCESSWIRE
News headline image
Jaguar Health to Host Investor Webcast Monday, November 14th at 8:30 AM Eastern Time Regarding Q3 2022 Financials & Corporate Updates
Via ACCESSWIRE
News headline image
Jaguar Health Reports Voting Results from 2022 Special Meeting of Stockholders
Via ACCESSWIRE
News headline image
Sandra M. Swain, MD, FACP, FASCO Joins Jaguar Health's Scientific Advisory Board
Via ACCESSWIRE
News headline image
Jaguar Health to Hold Investor Webcast Thursday, January 12th at 10:30 AM EST to Highlight Unmet Medical Need of Cancer Therapy-related Diarrhea and Jaguar's Mental Health Entheogen Therapeutics Initiative (ETI) to Discover Novel Therapies Derived from
Via ACCESSWIRE
News headline image
Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
Via ACCESSWIRE
News headline image
Jaguar Health Provides Updates on Presentation at the World Congress of Gastroenterology About Crofelemer for Pediatric Short Bowel Syndrome (SBS) and Congenital Diarrheal Disorders (CDD) by Third-Party Investigator
Via ACCESSWIRE
News headline image
Jaguar Animal Health Sponsors October 26th Episode of dvm360 Live! to Drive Awareness of Canalevia-CA1 and Participation in Jaguar’s Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
Via ACCESSWIRE
News headline image
Jaguar Health Announces Publication in Breast Cancer Research and Treatment of Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
Via ACCESSWIRE
News headline image
European Medicines Agency Grants Orphan Drug Designation for Crofelemer for Microvillus Inclusion Disease (MVID), a Second Rare Disease Indication
Via ACCESSWIRE
News headline image
Jaguar Animal Health Co-Sponsoring Closing Ceremony at Veterinary Cancer Society Annual Conference on October 15th to Drive Awareness of Jaguar's Take C.H.A.R.G.E. (Canine Health And ReGistry Exchange) Initiative
Via ACCESSWIRE
News headline image
Jaguar Health Subsidiary Napo Pharmaceuticals Announces Activation by FDA of Investigational New Drug (IND) Application for NP-300, a Novel Drug Candidate for the Symptomatic Relief and Treatment of Diarrhea from Cholera and Other Pathogens
Via ACCESSWIRE
News headline image
Jaguar Health to Present at Lytham Partners Fall 2022 Investor Conference on September 28th and at Ladenburg Thalmann 2022 Healthcare Conference on September 29th
Via ACCESSWIRE
News headline image
Jaguar Health Announces Submission of Investigational New Drug (IND) Application to FDA for Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Via ACCESSWIRE
News headline image
Jaguar Health Secures Additional Capital Through Sale of Royalty Rights Related to Future Crofelemer and Lechlemer Revenue Stream
Via ACCESSWIRE
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.